enow.com Web Search

  1. Ads

    related to: vegetable protein and kidney disease treatment medications guidelines for women

Search results

  1. Results from the WOW.Com Content Network
  2. Rice diet - Wikipedia

    en.wikipedia.org/wiki/Rice_diet

    The initial treatment was stopping all medication and putting the patient on a diet consisting of "white rice, sugar, fruit, fruit juices, vitamins and iron, and provided about 2000 calories, 20 grams of protein, and 700–1000 ml of liquid as fruit juices.

  3. Low-protein diet - Wikipedia

    en.wikipedia.org/wiki/Low-protein_diet

    A low-protein diet is used as a therapy for inherited metabolic disorders, such as phenylketonuria and homocystinuria, and can also be used to treat kidney or liver disease. Low protein consumption appears to reduce the risk of bone breakage, presumably through changes in calcium homeostasis. [1]

  4. Idiopathic hypercalcinuria - Wikipedia

    en.wikipedia.org/wiki/Idiopathic_hypercalcinuria

    The objective of treating IH is preventing nephrolithiasis or the formation of kidney stones. If blood calcium levels are normal, which can rule out hyperparathyroidism, treatment would begin with adopting a diet of ~800 mg of daily calcium, low salt intake, restricted animal protein intake, and increased net fluid intake. [8]

  5. A diet high in fruits and vegetables may reduce your heart ...

    www.aol.com/diet-high-fruits-vegetables-may...

    Medication intervention is still an important part of managing blood pressure, kidney disease and heart disease, Wesson said. This study shows that health systems should double down on making ...

  6. Nephrotic syndrome - Wikipedia

    en.wikipedia.org/wiki/Nephrotic_syndrome

    The treatment of kidney damage may reverse or delay the progression of the disease. [44] Kidney damage is treated by prescribing drugs: Corticosteroids : the result is a decrease in proteinuria and the risk of infection as well as a resolution of the edema.

  7. SGLT2 inhibitor - Wikipedia

    en.wikipedia.org/wiki/SGLT2_inhibitor

    Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.

  1. Ads

    related to: vegetable protein and kidney disease treatment medications guidelines for women